Of note, 34 patients with ALK fusion and 80 patients with EGFR mutant nonsquamous metastatic lung cancer were included in this study, and information on the benefit of atezolizumab in ALK fusion NSCLC was not reported separately (38). The gene discussed is ALK; the disease is non-small cell lung carcinoma.